A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Ribociclib (Primary) ; Buparlisib; Letrozole
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms LeeBLet
- Sponsors Novartis Pharmaceuticals
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2017.
- 11 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.